Format

Send to

Choose Destination
Chem Soc Rev. 2018 Oct 2. doi: 10.1039/c8cs00495a. [Epub ahead of print]

Antimicrobial glycoconjugate vaccines: an overview of classic and modern approaches for protein modification.

Author information

1
GSK, Via Fiorentina 1, 53100 Siena, Italy. roberto.x.adamo@gsk.com francesco.x.berti@gsk.com.

Abstract

Glycoconjugate vaccines obtained by chemical linkage of a carbohydrate antigen to a protein are part of routine vaccinations in many countries. Licensed antimicrobial glycan-protein conjugate vaccines are obtained by random conjugation of native or sized polysaccharides to lysine, aspartic or glutamic amino acid residues that are generally abundantly exposed on the protein surface. In the last few years, the structural approaches for the definition of the polysaccharide portion (epitope) responsible for the immunological activity has shown potential to aid a deeper understanding of the mode of action of glycoconjugates and to lead to the rational design of more efficacious and safer vaccines. The combination of technologies to obtain more defined carbohydrate antigens of higher purity and novel approaches for protein modification has a fundamental role. In particular, methods for site selective glycoconjugation like chemical or enzymatic modification of specific amino acid residues, incorporation of unnatural amino acids and glycoengineering, are rapidly evolving. Here we discuss the state of the art of protein engineering with carbohydrates to obtain glycococonjugates vaccines and future perspectives.

PMID:
30277489
DOI:
10.1039/c8cs00495a

Supplemental Content

Full text links

Icon for Royal Society of Chemistry
Loading ...
Support Center